The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Core binding factor
Gemtuzumab
Measurable residual disease
Transplant
inv(16)
t(8;21)
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
23
03
2023
revised:
04
07
2023
accepted:
21
07
2023
medline:
6
12
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Core binding factor acute myeloid leukemia (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete remission rate after induction and relatively good prognosis overall compared with other subtypes of AML, relapse risk after induction chemotherapy remains high. Optimizing treatment planning to promote recurrence free survival and increase the likelihood of survival after relapse is imperative to improving outcomes. Recent areas of research have included evaluation of the role of gemtuzumab in induction and consolidation, the relative benefit of increased cycles of high dose cytarabine in consolidation, the utility of hypomethylating agents and kinase inhibitors, and the most appropriate timing of stem cell transplant. Surveillance with measurable residual disease testing is increasingly being utilized for monitoring disease in remission, and ongoing investigation seeks to determine how to use this tool for early identification of patients who would benefit from proceeding to transplant. In this review, we outline the current therapeutic approach from diagnosis to relapse while highlighting the active areas of investigation in each stage of treatment.
Identifiants
pubmed: 37524647
pii: S0268-960X(23)00078-4
doi: 10.1016/j.blre.2023.101117
pii:
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Core Binding Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101117Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest Douglas Tremblay receives contracted research funding paid to his institution from CTI Biopharma, Astellas Pharma, and Gilead and consulting fees from CTI Biopharma, Novartis, AbbVie, Sierra Oncology, GSK, and Cogent. The rest of the authors have no conflicts of interest to disclose.